Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

People with MS had significantly higher deseasonalised serum 25-OHvD than unaffected siblings and healthy controls; the patients with MS were taking vitamin D supplementation at higher rates than either their siblings or healthy controls (data not shown).

Source: Risk score. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Study design awaiting verification.

Study design awaiting verification

The available source does not establish a sufficiently clear study design.

Meta-analysis unclear · Blinding unclear / not reported · Human research reported

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

A total of 302 participants were enrolled: 78 probands with MS, 121 of their unaffected siblings (including 6 monozygotic and 3 dizygotic twins), and 103 healthy controls (matched to the sibling group with respect to gender and decade of age) who had no first or second-degree relatives with MS.

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

A Risk Score for Predicting Multiple Sclerosis

Study design awaiting verification · PLoS ONE · 2016

Original publication title

A Risk Score for Predicting Multiple Sclerosis

Ruth Dobson; Sreeram Ramagopalan; Joanne Topping; Paul Smith; Bhavana Solanky; Klaus Schmierer; Declan Chard; Gavin Giovannoni

© 2016 Dobson et al

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

At a glance

Abstract: What objectives does the paper state?

Multiple sclerosis (MS) develops as a result of environmental influences on the genetically susceptible. Siblings of people with MS have an increased risk of both MS and demonstrating asymptomatic changes in keeping with MS. We set out to develop an MS risk score integrating both genetic and environmental risk factors. We used this score to identify siblings at extremes of MS risk and attempted to validate the score using brain MRI.

Source: Objective

Abstract: What methods does the paper describe?

78 probands with MS, 121 of their unaffected siblings and 103 healthy controls were studied. Personal history was taken, and serological and genetic analysis using the illumina immunochip was performed. Odds ratios for MS associated with each risk factor were derived from existing literature, and the log values of the odds ratios from each of the risk factors were combined in an additive model to provide an overall score. Scores were initially calculated using log odds ratio from the HLA-DRB1*1501 allele only, secondly using data from all MS-associated SNPs identified in the 2011 GWAS.

Subjects with extreme risk scores underwent validation studies. MRI was performed on selected individuals.

Source: Methods

Abstract: Interpretations

The risk score demonstrates an AUC on the threshold for clinical utility. Our score enables the identification of a high-risk sibling group to inform pre-symptomatic longitudinal studies.

Source: Interpretations

Abstract: Results

There was a significant difference in the both risk scores between people with MS, their unaffected siblings and healthy controls (p<0.0005). Unaffected siblings had a risk score intermediate to people with MS and controls (p<0.0005). The best performing risk score generated an AUC of 0.82 (95%CI 0.75 to 0.88).

Source: Results
Authors’ abstract

Objective

Multiple sclerosis (MS) develops as a result of environmental influences on the genetically susceptible. Siblings of people with MS have an increased risk of both MS and demonstrating asymptomatic changes in keeping with MS. We set out to develop an MS risk score integrating both genetic and environmental risk factors. We used this score to identify siblings at extremes of MS risk and attempted to validate the score using brain MRI.

Methods

78 probands with MS, 121 of their unaffected siblings and 103 healthy controls were studied. Personal history was taken, and serological and genetic analysis using the illumina immunochip was performed. Odds ratios for MS associated with each risk factor were derived from existing literature, and the log values of the odds ratios from each of the risk factors were combined in an additive model to provide an overall score. Scores were initially calculated using log odds ratio from the HLA-DRB1*1501 allele only, secondly using data from all MS-associated SNPs identified in the 2011 GWAS.

Subjects with extreme risk scores underwent validation studies. MRI was performed on selected individuals.

Results

There was a significant difference in the both risk scores between people with MS, their unaffected siblings and healthy controls (p<0.0005). Unaffected siblings had a risk score intermediate to people with MS and controls (p<0.0005). The best performing risk score generated an AUC of 0.82 (95%CI 0.75 to 0.88).

Interpretations

The risk score demonstrates an AUC on the threshold for clinical utility. Our score enables the identification of a high-risk sibling group to inform pre-symptomatic longitudinal studies.

Publication and source details

Original title: A Risk Score for Predicting Multiple Sclerosis

Ruth Dobson; Sreeram Ramagopalan; Joanne Topping; Paul Smith; Bhavana Solanky; Klaus Schmierer; Declan Chard; Gavin Giovannoni

PLoS ONE · 2016

Competing Interests: RD, SR, JT, and BS have no conflicts of interest to declare. KS is PI of trials sponsored by Novartis & Roche. He is involved in trials sponsored by Biogen, Genzyme, Teva, Merck Inc. and BIAL. Speaking honoraria from, and/or in an advisory role for, Novartis, Sanofi-Aventis, Merck-Serono and Merck Inc. DC has received research support from the MS Society of Great Britain and Northern Ireland, and the National Institute for Health Research University College London Hospitals Biomedical Research Centre.

He has received honoraria (paid to his employer) from Ismar Healthcare NV, Swiss MS Society, Excemed (previously Serono Symposia International Foundation), Merck, Bayer and Teva for faculty-led education work; Teva for advisory board work; meeting expenses from Merck, Teva, Novartis, the MS Trust and National MS Society; and has previously held stock in GlaxoSmithKline. He is a member of the MS Society of Great Britain and Northern Ireland's Biomedical Grant Review Panel. He is a member of the Data Safety Monitoring Committee for the PROXIMUS study, which is funded by National Multiple Sclerosis Society and Novartis.

Both of these roles are unpaid. GG has received research grant support from Bayer-Schering Healthcare, Biogen-Idec, GW Pharma, Merck Serono, Merz, Novartis, Teva and Sanofi-Aventis. He has received personal compensation for participating on Advisory Boards in relation to clinical trial design, trial steering committees and data and safety monitoring committees from: Bayer-Schering Healthcare, Biogen-Idec, Eisai, Elan, Fiveprime, Genzyme, Genentech, GSK, GW Pharma, Ironwood, Merck-Serono, Novartis, Pfizer, Roche, Sanofi-Aventis, Synthon BV, Teva, UCB Pharma and Vertex Pharmaceuticals. This does not alter our adherence to PLOS ONE policies on sharing data and materials.

  • Conceptualization: RD GG.

  • Formal analysis: RD SR PS KS DC GG.

  • Funding acquisition: RD.

  • Investigation: RD SR JT.

  • Methodology: RD SR GG.

  • Project administration: RD JT.

  • Resources: RD SR JT BS DC.

  • Supervision: RD GG.

  • Validation: PS KS DC.

  • Visualization: RD SR JT PS BS KS DC GG.

  • Writing: original draft: RD.

  • Writing: review & editing: RD SR JT PS BS KS DC GG.

* E-mail: ruth.dobson@qmul.ac.uk
© 2016 Dobson et al2016Dobson et alhttps://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.http://dx.doi.org/10.13039/501100000381Multiple Sclerosis Society940/10Dobson Ruth This study was funded by the MS Society of Great Britain and Northern Ireland (Grant ref 940/10). The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-12T19:55:33.534741+00:00

DOI: 10.1371/journal.pone.0164992 · PMC5089761